SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 649
AS - Asia 434
EU - Europa 253
SA - Sud America 5
Totale 1.341
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 644
SG - Singapore 237
IT - Italia 113
CN - Cina 101
ID - Indonesia 68
GB - Regno Unito 49
DE - Germania 37
HK - Hong Kong 12
FI - Finlandia 10
NL - Olanda 9
AT - Austria 8
KR - Corea 8
BR - Brasile 5
CA - Canada 4
LT - Lituania 4
BE - Belgio 3
FR - Francia 3
RU - Federazione Russa 3
TR - Turchia 3
CH - Svizzera 2
EE - Estonia 2
JP - Giappone 2
PL - Polonia 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
IN - India 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NI - Nicaragua 1
RS - Serbia 1
Totale 1.341
Salva come PNG Salva come JPEG
Città #
Santa Clara 395
Singapore 157
Jakarta 68
Chandler 39
London 20
Ferrara di Monte Baldo 18
Bologna 17
Falkenstein 14
Nuremberg 13
Hong Kong 10
Los Angeles 8
Florence 7
Milan 7
Shanghai 7
Frankfurt am Main 6
Hounslow 6
Lappeenranta 6
Yongsan-gu 6
Ashburn 5
Ferrara 5
Princeton 5
Chicago 4
Chiswick 4
Helsinki 4
Vienna 4
Brussels 3
Caldiero 3
Paris 3
Potomac 3
Southwark 3
Asciano 2
Beijing 2
Curtarolo 2
Forlì 2
Frankfurt Am Main 2
Gdansk 2
Islington 2
Livorno 2
Monza 2
Nakanishi 2
Naples 2
Ottawa 2
Parma 2
Rotterdam 2
Saha-gu 2
Sciacca 2
Sivas 2
Tallinn 2
Wandsworth 2
Americana 1
Amsterdam 1
Arezzo 1
Beauharnois 1
Belgrade 1
Brasília 1
Bremen 1
Brescia 1
Cologno Monzese 1
Forest City 1
Ibaiti 1
Kilburn 1
Lamezia Terme 1
Managua 1
Manassas 1
Minsk 1
Munich 1
New Bedfont 1
New Jersey 1
Newark 1
Pasadena 1
Plaistow 1
Prilep 1
Riga 1
Rockville 1
Rome 1
Saint Petersburg 1
San Jose 1
Seravezza 1
São José do Alegre 1
São Paulo 1
Tirana 1
Toronto 1
Trenton 1
Verona 1
Washington 1
Xi'an 1
Xuzhou 1
Totale 926
Salva come PNG Salva come JPEG
Nome #
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 36
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 34
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 33
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 32
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 29
The emerging role of cancer nanotechnology in the panorama of sarcoma 26
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 25
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 24
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 24
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 24
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 24
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 24
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 23
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 23
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 22
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 22
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 22
COVID and Lung Cancer 22
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 21
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 21
Challenges in lung cancer therapy during the COVID-19 pandemic 21
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 20
Biomarkers for immune checkpoint inhibitors--authors' reply 20
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 19
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 19
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 18
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 18
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 18
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 18
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 18
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 17
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 17
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 17
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 17
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 17
Recombinant transmembrane CD59 (CD59-TM) confers complement resistence to GPI-anchored protein detective melanoma cells. 15
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 15
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 15
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 14
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 14
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 14
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 14
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 14
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 13
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 13
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 13
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 13
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 13
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 13
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 13
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 13
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 13
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 12
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 12
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 12
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 12
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 12
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 12
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 12
The future of mesothelioma treatment: time to shift gear 12
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 12
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 11
Epigenetic immunomodulation of hematopoietic malignancies 11
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 11
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 11
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 11
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 10
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 10
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 10
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 10
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 10
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 10
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 10
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 10
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 10
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 10
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 10
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 9
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 9
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 9
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 9
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 9
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 9
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 9
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 8
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 8
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 8
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 8
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 6
Immune checkpoint blockade in malignant mesothelioma 6
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 6
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 6
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 6
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 5
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 4
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 1
Totale 1.425
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 148
Totale 31.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/2025963 81 125 172 29 237 234 67 18 0 0 0 0
Totale 1.425